BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37805421)

  • 1. [Prognostic significance and immune cell infiltration analysis of differentially expressed genes in malignant pleural mesothelioma].
    Wang N; Zhao QN; Yuan Q; Zhu BL; Wu W
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Sep; 41(9):641-647. PubMed ID: 37805421
    [No Abstract]   [Full Text] [Related]  

  • 2. KIAA0101 in Malignant Pleural Mesothelioma: A Potential Diagnostic and Prognostic Marker.
    Lin P; Zhao Y; Li X; Liang Z
    Comb Chem High Throughput Screen; 2022; 25(9):1498-1506. PubMed ID: 34238152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma.
    Reardon ES; Shukla V; Xi S; Gara SK; Liu Y; Straughan D; Zhang M; Hong JA; Payabyab EC; Kumari A; Richards WG; De Rienzo A; Hassan R; Miettinen M; Xi L; Raffeld M; Uechi LT; Li X; Wang R; Chen H; Hoang CD; Bueno R; Schrump DS
    J Thorac Oncol; 2021 Jan; 16(1):89-103. PubMed ID: 32927122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of CD24 gene in human malignant pleural mesothelioma and its relationship with prognosis].
    Li B; Zhou CX; Pu YQ; Qiu L; Mei W; Xiong W
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Mar; 41(3):168-176. PubMed ID: 37006141
    [No Abstract]   [Full Text] [Related]  

  • 5. Identification of Potential Hub Genes and Therapeutic Drugs in Malignant Pleural Mesothelioma by Integrated Bioinformatics Analysis.
    Zhang X; Yang L; Chen W; Kong M
    Oncol Res Treat; 2020; 43(12):656-671. PubMed ID: 33032291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression and clinical significance of COL1A1 and COL1A2 genes in malignant pleural mesothelioma tissues].
    Li B; Pu YQ; Li ZL; Zhao Y; Zi JJ; Xiong W
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2022 Jul; 40(7):487-494. PubMed ID: 35915937
    [No Abstract]   [Full Text] [Related]  

  • 7. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
    Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
    Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of glycolysis genes signature for predicting prognosis in malignant pleural mesothelioma by bioinformatics and machine learning.
    Xiao Y; Huang W; Zhang L; Wang H
    Front Endocrinol (Lausanne); 2022; 13():1056152. PubMed ID: 36523602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study.
    Arimura K; Hiroshima K; Nagashima Y; Nakazawa T; Ogihara A; Orimo M; Sato Y; Katsura H; Kanzaki M; Kondo M; Tagaya E
    BMC Cancer; 2023 Dec; 23(1):1206. PubMed ID: 38062416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.
    Alì G; Borrelli N; Riccardo G; Proietti A; Pelliccioni S; Niccoli C; Boldrini L; Lucchi M; Mussi A; Fontanini G
    J Thorac Oncol; 2013 Nov; 8(11):1389-95. PubMed ID: 24084442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression and prognostic significance of KAP1 gene in malignant pleural mesothelioma].
    Mei W; Wang XM; Liu RA; Xiong W; Zhang YP
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2024 Apr; 42(4):258-267. PubMed ID: 38677988
    [No Abstract]   [Full Text] [Related]  

  • 12. Analysis of the correlation between Zeste enhancer homolog 2 (EZH2) mRNA expression and the prognosis of mesothelioma patients and immune infiltration.
    Fan K; Zhang CL; Zhang BH; Gao MQ; Sun YC
    Sci Rep; 2022 Oct; 12(1):16583. PubMed ID: 36195655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
    Laszlo V; Hoda MA; Garay T; Pirker C; Ghanim B; Klikovits T; Dong YW; Rozsas A; Kenessey I; Szirtes I; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zöchbauer-Müller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Dome B; Hegedus B
    J Pathol; 2015 Oct; 237(2):203-14. PubMed ID: 26011651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma].
    Yu M; Yu M; Zhu LJ; Yuan XY; Zhang X
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):91-98. PubMed ID: 33691361
    [No Abstract]   [Full Text] [Related]  

  • 15. Identification of genes and pathways involved in malignant pleural mesothelioma using bioinformatics methods.
    Liu X; Qian K; Lu G; Chen P; Zhang Y
    BMC Med Genomics; 2021 Apr; 14(1):104. PubMed ID: 33849532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness.
    Inaguma S; Lasota J; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Schrump DS; Hassan R; Kasai K; Miettinen M; Ikeda H
    J Pathol; 2020 Feb; 250(2):205-216. PubMed ID: 31639216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
    Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
    J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
    J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.
    Andersen M; Trapani D; Ravn J; Sørensen JB; Andersen CB; Grauslund M; Santoni-Rugiu E
    Anticancer Res; 2015 Nov; 35(11):6223-9. PubMed ID: 26504055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genes and Pathways Involved in the Progression of Malignant Pleural Mesothelioma: A Meta-analysis of Genome-Wide Expression Studies.
    Mejia-Garcia A; Bonilla DA; Ramirez CM; Escobar-Díaz FA; Combita AL; Forero DA; Orozco C
    Biochem Genet; 2024 Feb; 62(1):352-370. PubMed ID: 37347449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.